Pilot Therapeutics Receives Patent for GLA Delivery

Pilot Therapeutics Receives Patent for GLA Delivery

WINSTON-SALEM, N.C.--Pilot Therapeutics recently received a patent (No.6,107,334) from the U.S. Patent and Trademark Office covering its deliveryformulation of gamma linolenic acid (GLA) for treating inflammatory disorders.

According to the company, the method delivers both GLA and a delta-5desaturase inhibitor to minimize GLA's possible increase on serum arachidonicacid. "The patent for our unique formulation of bioactive lipidtechnologies is a significant milestone in Pilot's development of novel dietarysupplements to treat inflammatory and proliferative diseases," said KennethTramposch, Ph.D., executive vice president and chief operating officer. For moreinformation, visit www.pilotp.com.